Stress Echocardiography Study With Regadenoson
- Registration Number
- NCT00907764
- Lead Sponsor
- Gilead Sciences
- Brief Summary
Regadenoson is approved in the US under the brand name Lexiscan for myocardial perfusion imaging. This study will test whether regadenoson is an appropriate stress agent for stress echocardiography.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria
- Patients with a clinically indicated dobutamine echocardiogram showing normal wall motion at rest and abnormal wall motion with stress
- Patients with a clinically indicated dipyridamole echocardiogram showing normal perfusion and wall motion at rest and abnormal perfusion with or without abnormal wall motion with stress
Exclusion Criteria
- Any condition precluding the safe administration of dobutamine, dipyridamole or SonoVue for echocardiography
- Pregnant or breast-feeding, or (if pre-menopausal), not practicing acceptable method of birth control
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Regadenoson with contrast agent (perfusion) regadenoson - Regadenoson alone regadenoson - Regadenoson with exercise regadenoson - Regadenoson with contrast agent regadenoson -
- Primary Outcome Measures
Name Time Method Cardiac wall motion and perfusion abnormalities at rest and with regadenoson stress, with regadenoson stress and low level exercise, and with regadenoson stress and an echocontrast agent. Within 12 minutes after dosing
- Secondary Outcome Measures
Name Time Method Various safety data will be collected, including adverse events, heart and blood pressure levels, ECG data, clinical laboratory results, and concomitant medications. Up to day 29 after dosing
Trial Locations
- Locations (1)
Northwick Park Hospital
🇬🇧Harrow, United Kingdom